{"name":"Catherine Bollard","slug":"catherine-bollard","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQd2NUT2JvNUFkV0hWdTJNQndWZ1Z5bHlFVEZhRG1ad0Q2Z1Y4ZjlEdFJvMFE0X0dMUjBjNVpmcEFxc3VpWk1SU2ppMFJIOUNoQVRsTGtTYkctUlpicFpTandzaGRDMUFzQUJMbmVYT1FER2FGaDVmbTVQdHZDckViMFdQMUNwdXYxSENnSUU0bXFuNzg?oc=5","date":"2024-07-19","type":"pipeline","source":"innovationdistrict.childrensnational.org","summary":"Closing the ‘Valley of Death’: Pioneering – and paying for – new therapies - innovationdistrict.childrensnational.org","headline":"Closing the ‘Valley of Death’: Pioneering – and paying for – new therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE42MUtmdFN3cHNCWU1HQi1nVnFTNzNBY0NxbzF2Mjc3bjVSYTJKckxRd3oyZjFFQ21sQnNsME95bkdHNmt2aXlkWjNXUG1iZjczUm1vQmp1YUNEVzFhY19B?oc=5","date":"2024-04-18","type":"regulatory","source":"nature.com","summary":"Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients","headline":"Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPMVlrMldZdkdLN2FReFB5MlU0c1ZuUGU0dUlKWkN1ME1qSVc0SFZSdEtGQ1ZrcFVkdmxjdENZVm80NHRJMlR4VENLZDFpdFZyTnpEVEYtWmpoRWwzZ3Juc1B3bTI5TDZBMFlIZ1V1VW1QZmFBSjhKbHQ1VkdZSXBMWXpiVjdkNEtzRTFiQk5ReTJXeEYzbWhhZmsyTmdveXpiNmhUV2owMkRVQQ?oc=5","date":"2021-02-11","type":"pipeline","source":"innovationdistrict.childrensnational.org","summary":"Children’s National spin-out cell therapy company receives funding - innovationdistrict.childrensnational.org","headline":"Children’s National spin-out cell therapy company receives funding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxOdDJNZkhoSXBMdlRDd3ktSVhSb1hmWDNBekQ2WFI4SEhPWHNMd0Qzc2ZvRjJ6cWRvOWVCeVpvWnRkUG03QnRrZzZCRjNiNmtRM01ZNXNRUmFzVUdxR1JNVlZvUDlFdEpYdmFTX2VHQ3A0S2swbmNwcjh5MXdmUWhVQ21qeFFVVW5FS01CRjlrLXVvaWg5UnVKUHgzVXd4UkY1eUY1S2hITTZWcnBEb1hEbDNFU08ydll1VWZFYzJkQzhhc2M0TUZmQWpIdGw0ZXlrQWwxT08yZm5DUQ?oc=5","date":"2020-12-07","type":"pipeline","source":"Healio","summary":"Gene-edited stem cells show curative potential for beta-thalassemia, sickle cell disease - Healio","headline":"Gene-edited stem cells show curative potential for beta-thalassemia, sickle cell disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNeHRHUkp3OHpHejVpVjJkclNpdEFWdlQwS3hrdE9tc2VGZ3p5dGJUMGx4eWxmaEdUVFZZU1RCRDR0YnFzR0VJUTRqck1yMy1WT2NaZm9xM1R0a2hXYUlwTGM2Tl9fZVFISHVSWW9lUkJkZVJKQUN1c1VtOHV1RUY2TmJMa1lzbnRtWHFmLUxnOFJMQmUyS2RxdE93ZEFXZC1GVmZKOUFuTFU3eU5kWXZDU0Y1THBLdERYY2pKdEQ3RUlXNjhQbnR4YUtSYmJtYXRn?oc=5","date":"2020-12-05","type":"pipeline","source":"Healio","summary":"CAR-T confers durable clinical benefit in high-risk indolent non-Hodgkin lymphoma - Healio","headline":"CAR-T confers durable clinical benefit in high-risk indolent non-Hodgkin lymphoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQV1JLZ1FQcEVCY2tQVGE4VWw5UE4wd3RSRHdfUWVPUzNsVUJERWdlODlMY0ktQW5PZGkxMVpIT2lvWFV6aEVldnl6Y0tHZWw0dDFGS0NSWTd4LUVMZUhhcE1RVGpwbll3WDhEOU10SWZMc2tXMWpLaDdXd2lnSEdlVFpkc3lhZGZTX1BFR2R1R1Z5OTVVV3B5Rlc1bG9Pb3F1XzY4UTEtbVIyVjR6c2h1SDRn?oc=5","date":"2020-11-05","type":"pipeline","source":"innovationdistrict.childrensnational.org","summary":"Catherine Bollard, M.D., M.B.Ch.B., named next editor-in-chief of Blood Advances - innovationdistrict.childrensnational.org","headline":"Catherine Bollard, M.D., M.B.Ch.B., named next editor-in-chief of Blood Advances","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNS1JmZFJEZ3ZCd3pydmRBQm1nQllCcU1JZ0N2ZUFjbEpRVWdteElSSHQ3UXJUSzZUaHctaVU2blRPYk1oTW5sa3lHbFhCZVlZcUpjMFdHSW9uaGZydTJ1NXZ3LVRfeFZzWi1rdlEyQURsNGgtdFhOMHlseE9JU3NIQkMzd1Q0OGpUdk9RRGtHTGM?oc=5","date":"2017-08-29","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Will Cell and Gene Therapies Reach a Tipping Point? - Genetic Engineering and Biotechnology News","headline":"Will Cell and Gene Therapies Reach a Tipping Point?","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}